Our Therapies

We currently have one approved medication on the market, as well as a number of late-stage and pre-clinical programs in our pipeline.

Adverse events should be reported. Please report to your country competent authority.

To report negative side effects of prescription drugs to the FDA, visit www.fda.gov/medwatch, or call 1-800-FDA-1088 (1-800-332-1088).

If you are a UK health care professional, reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.

Adverse events should also be reported to Immunocore, through the channels below.

United States:

medical.information@immunocore.com
844-IMMUNO1

Europe/Rest of World:

medinfo.eu@immunocore.com
+44 203 996 7074 (European local toll)
+00 800-74451111 (toll-free)

KIMMTRAK in the United States

KIMMTRAK (tebentafusp-tebn)
(Injection for Intravenous Use 100 mcg/0.5 mL)

U.S. Full Prescribing Information including Boxed WARNING for CRS

U.S. Patient Information including BOXED WARNING for CRS

Information for Colorado Prescribers of Prescription Drugs

U.S. Product website

KIMMTRAK▼ in the United Kingdom

KIMMTRAK (tebentafusp)
(Concentrate for Solution for Infusion 200 mcg/mL)

Reporting of side effects

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/.

UK Summary of Product Characteristics

UK Patient Information Leaflet

UK product website (this website contains promotional information intended for healthcare professionals)